canertinib dihydrochloride has been researched along with bms 387032 in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (bms 387032) | Trials (bms 387032) | Recent Studies (post-2010) (bms 387032) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 76 | 3 | 56 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | bms 387032 (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0103 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.48 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.048 | |
| Vitamin K-dependent protein C | Homo sapiens (human) | 0.264 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.48 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.7538 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.48 | |
| Cyclin-A2 | Homo sapiens (human) | 0.0427 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.925 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.046 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0426 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.925 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.925 | |
| Cannabinoid receptor 2 | Mus musculus (house mouse) | 0.062 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.0772 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.1078 | |
| Cyclin-H | Homo sapiens (human) | 0.0823 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.1027 | |
| Cyclin-A1 | Homo sapiens (human) | 0.021 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.34 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.34 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.48 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for canertinib dihydrochloride and bms 387032
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |